• Abcellera Biologics director John S. Montalbano bought 20,000 common shares at USD 4.77.
• Directly held stake rose to 241,000 common shares.
• He also reported 5,000 common shares held indirectly by his spouse.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001834423-26-000004), on May 18, 2026, and is solely responsible for the information contained therein.